Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Phase 1 Completed 133 enrolled AbbVie

RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics of ABT-333 in healthy volunteers and the antiviral activity in HCV infected subjects.

Timeline

Start: 2008-06
Primary completion: 2009-02
Completion: —

Publications

Results Mensing S, Polepally AR, Konig D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1. Epub 2015 Nov 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasabuvir	Small molecule	10 mg	—
Subject	dasabuvir	Small molecule	100 mg	—
Subject	dasabuvir	Small molecule	300 mg	—
Subject	dasabuvir	Small molecule	1200 mg	—

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Summary

Timeline

Publications

Drugs

Indications